Compared with placebo, ACEI/ARB treatment did significantly reduce the subsequent use of oral antihyperglycaemic treatment or insulin among patients with new-onset DM (RR = 0.70, 95% CI: 0.58–0.84, p = 0.0002) (Additional file 4: Fig. S14). Here, INS is linked to diabetes mellitus.